- Home
- VRCA vs CNTX Comparison
VRCA vs CNTX Comparison
Compare VRCA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- CNTX
- Stock Information
- Founded
- VRCA 2013
- CNTX 2015
- Country
- VRCA United States
- CNTX United States
- Employees
- VRCA N/A
- CNTX N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- CNTX Health Care
- Exchange
- VRCA Nasdaq
- CNTX Nasdaq
- Market Cap
- VRCA 58.0M
- CNTX 60.1M
- IPO Year
- VRCA 2018
- CNTX 2021
- Fundamental
- Price
- VRCA $0.54
- CNTX $0.71
- Analyst Decision
- VRCA Hold
- CNTX Strong Buy
- Analyst Count
- VRCA 5
- CNTX 5
- Target Price
- VRCA $6.00
- CNTX $6.70
- AVG Volume (30 Days)
- VRCA 352.1K
- CNTX 93.3K
- Earning Date
- VRCA 03-11-2025
- CNTX 05-07-2025
- Dividend Yield
- VRCA N/A
- CNTX N/A
- EPS Growth
- VRCA N/A
- CNTX N/A
- EPS
- VRCA N/A
- CNTX N/A
- Revenue
- VRCA $7,566,000.00
- CNTX N/A
- Revenue This Year
- VRCA $93.38
- CNTX N/A
- Revenue Next Year
- VRCA $127.27
- CNTX N/A
- P/E Ratio
- VRCA N/A
- CNTX N/A
- Revenue Growth
- VRCA 47.66
- CNTX N/A
- 52 Week Low
- VRCA $0.54
- CNTX $0.65
- 52 Week High
- VRCA $11.41
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- VRCA 33.47
- CNTX 37.75
- Support Level
- VRCA $0.54
- CNTX $0.65
- Resistance Level
- VRCA $0.68
- CNTX $0.76
- Average True Range (ATR)
- VRCA 0.07
- CNTX 0.07
- MACD
- VRCA -0.01
- CNTX -0.01
- Stochastic Oscillator
- VRCA 0.15
- CNTX 22.40
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.